Skip to content

Study · Animal study (in vivo) · rat · 2005

19 results

Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34).

Alkhiary YM, Gerstenfeld LC, Krall E, Westmore M, Sato M, Mitlak BH, Einhorn TA

The Journal of bone and joint surgery. American volume1 Apr 2005Cited by 228 (Europe PMC)

PMID15805200 (opens in a new tab)DOI10.2106/jbjs.d.02115 (opens in a new tab)PepBankPUB-15805200
Publisher pagePubMedAsk about this study
Jump to 19 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study19

19 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, PTH increased torsional strength versus vehicle by day 21.

    In plain wordsIn rats with femoral fractures, PTH increased torsional strength versus vehicle by day 21.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTorsional strength at day 21
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 21, calluses from the group treated with 30 mug of PTH showed significant increases over the controls with respect to torsional strength, stiffness, bone mineral content, bone mineral density, and cartilage volume.
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, PTH increased stiffness versus vehicle by day 21.

    In plain wordsIn rats with femoral fractures, PTH increased stiffness versus vehicle by day 21.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseStiffness at day 21
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 21, calluses from the group treated with 30 mug of PTH showed significant increases over the controls with respect to torsional strength, stiffness, bone mineral content, bone mineral density, and cartilage volume.
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, PTH increased bone mineral content versus vehicle by day 21.

    In plain wordsIn rats with femoral fractures, PTH increased bone mineral content versus vehicle by day 21.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone mineral content at day 21
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 21, calluses from the group treated with 30 mug of PTH showed significant increases over the controls with respect to torsional strength, stiffness, bone mineral content, bone mineral density, and cartilage volume.
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, PTH increased bone mineral density versus vehicle by day 21.

    In plain wordsIn rats with femoral fractures, PTH increased bone density versus vehicle by day 21.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone mineral density at day 21
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 21, calluses from the group treated with 30 mug of PTH showed significant increases over the controls with respect to torsional strength, stiffness, bone mineral content, bone mineral density, and cartilage volume.
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, PTH increased cartilage volume versus vehicle by day 21.

    In plain wordsIn rats with femoral fractures, PTH increased cartilage volume versus vehicle by day 21.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCartilage volume at day 21
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 21, calluses from the group treated with 30 mug of PTH showed significant increases over the controls with respect to torsional strength, stiffness, bone mineral content, bone mineral density, and cartilage volume.
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, PTH at the lower dose increased bone mineral content versus vehicle by day 35.

    In plain wordsIn rats with femoral fractures, lower-dose PTH increased bone mineral content versus vehicle by day 35.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone mineral content at day 35
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    5 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 35, both groups treated with PTH showed significant increases in bone mineral content and density and total osseous tissue volume, and they demonstrated significant decreases in void space and cartilage volume (p < 0.05).
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, PTH at the higher dose increased bone mineral content versus vehicle by day 35.

    In plain wordsIn rats with femoral fractures, higher-dose PTH increased bone mineral content versus vehicle by day 35.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone mineral content at day 35
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 35, both groups treated with PTH showed significant increases in bone mineral content and density and total osseous tissue volume, and they demonstrated significant decreases in void space and cartilage volume (p < 0.05).
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, lower-dose PTH increased bone mineral density versus vehicle by day 35.

    In plain wordsIn rats with femoral fractures, lower-dose PTH increased bone density versus vehicle by day 35.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone mineral density at day 35
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    5 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 35, both groups treated with PTH showed significant increases in bone mineral content and density and total osseous tissue volume, and they demonstrated significant decreases in void space and cartilage volume (p < 0.05).
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, higher-dose PTH increased bone mineral density versus vehicle by day 35.

    In plain wordsIn rats with femoral fractures, higher-dose PTH increased bone density versus vehicle by day 35.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone mineral density at day 35
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 35, both groups treated with PTH showed significant increases in bone mineral content and density and total osseous tissue volume, and they demonstrated significant decreases in void space and cartilage volume (p < 0.05).
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, lower-dose PTH increased total osseous tissue volume versus vehicle by day 35.

    In plain wordsIn rats with femoral fractures, lower-dose PTH increased bone tissue volume versus vehicle by day 35.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal osseous tissue volume at day 35
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    5 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 35, both groups treated with PTH showed significant increases in bone mineral content and density and total osseous tissue volume, and they demonstrated significant decreases in void space and cartilage volume (p < 0.05).
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, higher-dose PTH increased total osseous tissue volume versus vehicle by day 35.

    In plain wordsIn rats with femoral fractures, higher-dose PTH increased bone tissue volume versus vehicle by day 35.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal osseous tissue volume at day 35
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 35, both groups treated with PTH showed significant increases in bone mineral content and density and total osseous tissue volume, and they demonstrated significant decreases in void space and cartilage volume (p < 0.05).
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, lower-dose PTH decreased void space versus vehicle by day 35.

    In plain wordsIn rats with femoral fractures, lower-dose PTH decreased void space versus vehicle by day 35.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseVoid space at day 35
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    5 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 35, both groups treated with PTH showed significant increases in bone mineral content and density and total osseous tissue volume, and they demonstrated significant decreases in void space and cartilage volume (p < 0.05).
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, higher-dose PTH decreased void space versus vehicle by day 35.

    In plain wordsIn rats with femoral fractures, higher-dose PTH decreased void space versus vehicle by day 35.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseVoid space at day 35
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 35, both groups treated with PTH showed significant increases in bone mineral content and density and total osseous tissue volume, and they demonstrated significant decreases in void space and cartilage volume (p < 0.05).
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  14. 14AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, lower-dose PTH decreased cartilage volume versus vehicle by day 35.

    In plain wordsIn rats with femoral fractures, lower-dose PTH decreased cartilage volume versus vehicle by day 35.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCartilage volume at day 35
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    5 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 35, both groups treated with PTH showed significant increases in bone mineral content and density and total osseous tissue volume, and they demonstrated significant decreases in void space and cartilage volume (p < 0.05).
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  15. 15AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, higher-dose PTH decreased cartilage volume versus vehicle by day 35.

    In plain wordsIn rats with femoral fractures, higher-dose PTH decreased cartilage volume versus vehicle by day 35.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCartilage volume at day 35
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    By day 35, both groups treated with PTH showed significant increases in bone mineral content and density and total osseous tissue volume, and they demonstrated significant decreases in void space and cartilage volume (p < 0.05).
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  16. 16AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, higher-dose PTH increased torsional strength versus vehicle at day 35.

    In plain wordsIn rats with femoral fractures, higher-dose PTH increased torsional strength versus vehicle at day 35.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTorsional strength at day 35
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    Torsional strength was significantly increased at this time-point in the group treated with 30 mug of PTH (p < 0.05).
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  17. 17AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, higher-dose PTH produced sustained torsional strength increases versus vehicle after treatment stopped.

    In plain wordsIn rats with femoral fractures, higher-dose PTH maintained greater torsional strength than vehicle after treatment stopped.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTorsional strength at day 84
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneous · 35 daysAs given in this study (rat).

    Source sentences

    Summary
    While dosing was discontinued on day 35, analyses performed after eighty-four days in the group treated with 30 mug of PTH showed sustained increases over the controls with respect to torsional strength and bone mineral density.
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  18. 18AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, higher-dose PTH produced sustained bone mineral density increases versus vehicle after treatment stopped.

    In plain wordsIn rats with femoral fractures, higher-dose PTH maintained greater bone density than vehicle after treatment stopped.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone mineral density at day 84
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 mug/kg daily · subcutaneous · 35 daysAs given in this study (rat).

    Source sentences

    Summary
    While dosing was discontinued on day 35, analyses performed after eighty-four days in the group treated with 30 mug of PTH showed sustained increases over the controls with respect to torsional strength and bone mineral density.
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.
  19. 19AnimalAnimal study (in vivo)Efficacy outcome

    In rats with femoral fractures, PTH did not change osteoclast density at the measured time points.

    In plain wordsIn rats with femoral fractures, PTH did not change osteoclast density at the measured time points.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeOsteoclast density
    Study

    ratn: not reported in source

    Closed femoral fracture
    Comparator
    Vehicle control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    No change was noted in osteoclast density at the time-points measured, suggesting that treatment with PTH enhanced bone formation but did not induce bone resorption.
    2 context sentences
    Summary · context
    Two hundred and seventy male Sprague-Dawley rats underwent standard, closed femoral fractures and were divided into three groups that were administered daily subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
    Summary · context
    The dosing was administered for up to thirty-five days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 2Results postedNCT01279187

The Impact of Parathyroid Hormone (PTH) on Craniofacial Osseous Regeneration in Bone

University of Michigann = 27Feb 2011 to Nov 2015

Implant

Trial pageClinicalTrials.govUpdated 7 Feb 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.